Jason Drew Smith Sells 1,519 Shares of Urogen Pharma (NASDAQ:URGN) Stock

Urogen Pharma (NASDAQ:URGN) General Counsel Jason Smith sold 1,519 shares of the firm’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $42.54, for a total value of $64,618.26. Following the sale, the general counsel directly owned 53,141 shares of the company’s stock, valued at $2,260,618.14. The trade was a 2.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Urogen Pharma Stock Up 1.8%

URGN stock traded up $0.79 during mid-day trading on Wednesday, hitting $44.60. 648,104 shares of the company were exchanged, compared to its average volume of 807,203. The firm has a market capitalization of $2.18 billion, a P/E ratio of -22.61 and a beta of 1.57. The business has a fifty day simple moving average of $43.02 and a 200-day simple moving average of $31.15. Urogen Pharma has a 12-month low of $15.86 and a 12-month high of $50.81.

Urogen Pharma (NASDAQ:URGN) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The firm had revenue of $72.46 million for the quarter, compared to analyst estimates of $63.55 million. Research analysts predict that Urogen Pharma will post -0.2 EPS for the current year.

Institutional Trading of Urogen Pharma

A number of institutional investors have recently bought and sold shares of URGN. Partners Capital Investment Group LLP acquired a new stake in Urogen Pharma during the 2nd quarter worth approximately $566,000. Rice Hall James & Associates LLC purchased a new position in Urogen Pharma in the second quarter worth $11,064,000. California State Teachers Retirement System lifted its holdings in Urogen Pharma by 1,605.5% in the first quarter. California State Teachers Retirement System now owns 38,750 shares of the company’s stock valued at $697,000 after acquiring an additional 36,478 shares during the period. Swiss National Bank acquired a new stake in Urogen Pharma in the first quarter valued at $1,399,000. Finally, Deutsche Bank AG purchased a new stake in shares of Urogen Pharma during the 2nd quarter worth $1,897,000. 91.29% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently commented on URGN shares. Oppenheimer raised their price target on Urogen Pharma from $40.00 to $50.00 and gave the stock an “outperform” rating in a research report on Thursday, July 16th. TD Cowen boosted their price objective on Urogen Pharma from $50.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a research note on Friday, July 17th. Guggenheim raised their target price on Urogen Pharma from $42.00 to $58.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Finally, HC Wainwright lifted their target price on Urogen Pharma from $45.00 to $75.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $50.38.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.